Middle East & Africa Insulin Market Size & Outlook
Middle East & Africa insulin market, 2018-2030 (US$M)
Related Markets
MEA insulin market highlights
- The MEA insulin market generated a revenue of USD 694.4 million in 2023.
- The market is expected to grow at a CAGR of 3.7% from 2024 to 2030.
- In terms of segment, insulin analog was the largest revenue generating type in 2023.
- Insulin Analog is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 694.4 million |
| Market revenue in 2030 | USD 898.1 million |
| Growth rate | 3.7% (CAGR from 2023 to 2030) |
| Largest segment | Insulin analog |
| Fastest growing segment | Insulin Analog |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Insulin Analog, Human Insulin |
| Key market players worldwide | Novo Nordisk A/S ADR, Eli Lilly and Co, Sanofi SA, United Laboratories International Holdings Ltd, Biocon, Wockhardt, Boehringer Ingelheim Pharma, Tonghua Dongbao Pharmaceutical, Julphar |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.5% of the global insulin market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 7,094.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Insulin Market Scope
Insulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa insulin market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to insulin market will help companies and investors design strategic landscapes.
Insulin analog was the largest segment with a revenue share of 86.45% in 2023. Horizon Databook has segmented the Middle East & Africa insulin market based on insulin analog, human insulin covering the revenue growth of each sub-segment from 2018 to 2030.
Major challenges faced by the Middle East and North Africa (MENA) insulin market include lack of health awareness among people in the lower socioeconomic classes. However, in recent years, health awareness campaigns and government initiatives have boosted the overall awareness over the forecast period.
Increasing prevalence of diabetes in MENA countries is anticipated to drive market growth. According to the IDF, around 3.4 million people were affected by diabetes mellitus in 2022 in Kuwait, followed by 990,900 in the UAE, 1.60 million in Afghanistan, 4.27 million in Saudi Arabia, 183,000 in Palestine, 2.01 million in Algeria, 396,100 in Lebanon, and 119,800 in Bahrain.
Growing technological advancements in R&D of drug delivery may increase the prescription rate for a product, driving the market. For instance, in January 2022, the Saudi Health Council and Sanofi signed an agreement to collaborate on various initiatives in the R&D of diabetes treatments.
Reasons to subscribe to Middle East & Africa insulin market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa insulin market databook
-
Our clientele includes a mix of insulin market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa insulin market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa insulin market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA insulin market size, by country, 2018-2030 (US$M)
Middle East & Africa Insulin Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
